Literature DB >> 6832195

Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals.

V W Steinijans, E Diletti.   

Abstract

For a two-way cross-over design, which appears to be the most common experimental design in bioavailability studies, 95%-confidence limits for expected bioavailability can be obtained by classical analysis of variance (ANOVA). If symmetry of the confidence interval is desired about zero (differences) or unity (ratios) rather than about the corresponding point estimator, Westlake's modification can be used. Two nonparametric methods and their adaptations to bioavailability ratios are reviewed, one based on Wilcoxon's signed rank test (Tukey), and the other on Pitman's permutation test. The necessary assumptions and the merits of these procedures are discussed. The methods are illustrated by an example of a comparative bioavailability study. A FORTRAN program facilitating the procedures is available from the authors upon request.

Mesh:

Substances:

Year:  1983        PMID: 6832195     DOI: 10.1007/bf00613939

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS.

Authors:  J E GRIZZLE
Journal:  Biometrics       Date:  1965-06       Impact factor: 2.571

2.  Per cent absorbed time plots derived from blood level and/or urinary excretion data.

Authors:  J G WAGNER; E NELSON
Journal:  J Pharm Sci       Date:  1963-06       Impact factor: 3.534

3.  Symmetrical confidence intervals for bioequivalence trials.

Authors:  W J Westlake
Journal:  Biometrics       Date:  1976-12       Impact factor: 2.571

4.  Digoxin bioavailability: evaluation of a generic tablet and proposed FDA guidelines.

Authors:  W G Kramer; A J Kolibash; M S Bathala; J A Visconti; R P Lewis; R H Reuning
Journal:  J Pharm Sci       Date:  1977-12       Impact factor: 3.534

Review 5.  Use of statistical methods in evaluation of in vivo performance of dosage forms.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1973-10       Impact factor: 3.534

6.  The use of non-parametric methods in the statistical analysis of the two-period change-over design.

Authors:  G G Koch
Journal:  Biometrics       Date:  1972-06       Impact factor: 2.571

7.  Use of confidence intervals in analysis of comparative bioavailability trials.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

8.  The analysis of the two-period repeated measurements crossover design with application to clinical trials.

Authors:  S Wallenstein; A C Fisher
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

9.  Determining the probability of an important difference in bioavailability.

Authors:  B E Rodda; R L Davis
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

10.  MANOVA of statistical moments in biopharmaceutical studies: a numerical example with three equally spaced doses of amoxicillin.

Authors:  J L Vila; R Martínez; J Giménez; M Llabrés
Journal:  J Pharmacokinet Biopharm       Date:  1980-08
View more
  32 in total

1.  Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India.

Authors:  Shyam Sundar; Prabhat K Sinha; Susan A Dixon; Renata Buckley; Ann K Miller; Khadeeja Mohamed; Mahir Al-Banna
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  The relevance of residence time theory to pharmacokinetics.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  A novel type II membrane receptor up-regulated by IFN-alpha in fibroblasts functions in cell proliferation through the JAK-STAT signalling pathway.

Authors:  L-D Liu; C-H Dong; H-J Shi; H-L Zhao; L-C Wang; S-H Ma; Q-H Li
Journal:  Cell Prolif       Date:  2006-04       Impact factor: 6.831

4.  Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers.

Authors:  T Hedner; J Hedner; A Gelin-Friberg; M L Huang; S Van de Poel; R Woestenborghs; A Van Peer; J Heykants
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Bioavailability study of paracetamol tablets in saliva and urine.

Authors:  P Retaco; M González; M T Pizzorno; M G Volonté
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

6.  Saturable rate of cefatrizine absorption after oral administration to humans.

Authors:  B G Reigner; W Couet; J P Guedes; J B Fourtillan; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1990-02

7.  The bioavailability of three altretamine formulations.

Authors:  E A Runhaar; J P Neijt; J J Holthuis; D de Vos
Journal:  Pharm Weekbl Sci       Date:  1989-12-15

8.  Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man.

Authors:  U Fuhr; K Klittich; A H Staib
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

9.  [Bioavailability study of micronutrients].

Authors:  K Pietrzik; T Remer
Journal:  Z Ernahrungswiss       Date:  1989-06

10.  Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination.

Authors:  G Ruf; S Gera; H G Luus; D Trenk; N de la Rey; K Löffler; W Schulz; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.